Moreover, results from this research demonstrated that cells from AML patients expressing CD36 were less susceptible to chemotherapeutic agents such as Ara-C compared to cells that did not express CD3628; nevertheless, there are other drugs that must be investigated in further studies to support CD36 as a treatment target. The gene discussed is CD36; the disease is acute myeloid leukemia.